Global Neuroblastoma Drugs Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|神經母細胞瘤治療藥的全球市場 (2020年∼2027年) Global Neuroblastoma Drugs Market - 2020-2027|
|出版日期: 2021年05月12日||內容資訊: 英文 180 Pages||
全球神經母細胞瘤治療藥市場成長的主要因素有神經母細胞瘤的發病率上升，及抗GD2抗體的需求增加，研究開發 (R&D) 活動的活躍等。按地區劃分，北美是最大的市場，而亞太國家也有望大幅增長。
The Global Neuroblastoma Drugs Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Neuroblastoma is a type of tumour that begins in certain very early forms of nerve cells, most often found in an embryo or foetus. The term neuro refers to nerves, while blastoma refers to cancer that primarily affects immature or developing cells. It occurs most often in infants and young children, and it is rare in children older than ten years. Most neuroblastomas begin in sympathetic nerve ganglia in the abdomen; about half of these start in the adrenal gland, and most of the rest start in sympathetic ganglia near the spine, chest or neck, or pelvis.
It accounts for about 6% of all cancers in children. According to the American cancer society, there are about 800 new cases of neuroblastoma each year in the United States. The average age of children when they are diagnosed is about 1 to 2 years. In rare cases, neuroblastoma is detected by ultrasound even before birth. Nearly 90% of cases are diagnosed by age 5. Signs and symptoms of neuroblastoma vary depending on what part of the body is affected. In the abdomen, it causes abdominal pain, a mass under the tender skin when touched, Changes in bowel habits, such as diarrhoea or constipation. In chest may cause signs and symptoms such as Wheezing, Chest pain, Changes to the eyes, including drooping eyelids and unequal pupil size. The treatment for neuroblastoma depends on the child's age and the stage of their cancer. It may include surgery, chemotherapy, radiation therapy, immunotherapy, a stem cell transplant.
The global Neuroblastoma Drugs market growth is driven by the growing incidence of neuroblastoma, Rising demand for anti-GD2 antibodies. Also, increasing R&D activities for relapsed refractory neuroblastoma is anticipated the major factors to drive the neuroblastoma drugs market.
Rising demand for anti-GD2 antibodies, is expected to drive the global Neuroblastoma Drugs market during the forecast period.
Identifying the therapeutic targets on cancer cells or within the signaling cascade that leads to tumor growth is a promising field in cancer research. GD2 (0-acetyl-GD2 ganglioside) is a cell surface antigen that is overexpressing GD2 receptors can be eliminated by using specific monoclonal antibodies against GD2. For instance, Dinutuximab was the first identified drug acting as an anti-GD2-specific monoclonal antibody, which was approved for the treatment of neuroblastoma. The main reason for the boost of neuroblastoma drug sales such as anti-GD2 is their ability to provide site-specific action. As a result, these drugs do not pose any cytotoxic effects in the body that tend to impact the quality of life of neuroblastoma patients. Therefore, physicians are prescribing anti-GD2 monoclonal antibodies as neuroblastoma drugs for the treatment of neuroblastoma. These factors will increase the global market growth during the forecast period.
High cost of treatment, is expected to hinder the global Neuroblastoma Drugs market during the forecast period.
In low and medium-income countries where the government's health insurance is only 40%, the cost of treatment can be a fortune for patients. As per the data published in National Library of Medicine NIH, the medical cost of neuroblastoma treatment depends upon the risk level. For low risk 27,748.62 USD, middle risk 30,831.80 USD and high risk 100,203.35 USD respectively. This factor is restricting the market growth.
COVID-19 Impact Analysis
The COVID-19 pandemic has negatively impacted healthcare systems globally and majorly on the neuroblastoma drugs market. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the cancers. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually.
Based on the Drug Type, the global Neuroblastoma drugs market is segmented into Dinutuximab, Cisplatin, Doxorubicin, Vincristine, Etoposide, Others
Dinutuximab accounts the largest market share in drug type.
Dinutuximab is the first identified drug acting as an anti-GD2-specific monoclonal antibody approved by the FDA to treat neuroblastoma. It is approved to be used with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (IL-2), and 13-cis retinoic acid to treat by providing site-specific action. Besides, these drugs do not pose any cytotoxic effects in the body that tend to impact the quality of life of neuroblastoma patients.
Doxorubicin under tradename Adriamycin is a most powerful chemotherapy drug approved by FDA to treat neuroblastoma. For instance, Johnson & Johnson operates its business under three segments, which include pharmaceutical, medical devices, and consumer. The company's key offering includes DOXIL which is a chemotherapy drug indicated for the treatment of neuroblastoma. Doxil is anthracycline topoisomerase II inhibitor inhibits nucleic acid synthesis by binding to DNA. It has side effects like hair loss, heart damage, bone marrow suppression.
Cisplatin is one of the chemotherapy drugs used to treat neuroblastoma. Cisplatin is a platinum-based antineoplastic medication. It works by binding to DNA and inhibiting its replication. Common side effects include bone marrow suppression, hearing problems, kidney damage. For instance, ETOPOPHOS by Bristol-Myers Squibb is indicated for the treatment of localized and unresectable neuroblastoma in combination with cisplatin.
Vincristine is also called leurocristine and marketed under the brand names Oncovin, Vincrex, Vincasar PFS is a chemotherapy medication used to treat neuroblastoma. It works partly by binding to the tubulin protein, stopping the tubulin dimers from polymerizing to form microtubules, causing the cell to be unable to separate its chromosomes during the metaphase. The cell then undergoes apoptosis. Some side effects may include neuropathic pain, lung damage, or low white blood cells, which increases the risk of infection. For instance, Vincrex is a Bristol-Myers Squibb chemotherapy drug indicated alone or in combination with other chemotherapy drugs to treat neuroblastoma.
Etoposide, sold under the brand name ETOPOPHOS, Vepesid is a chemotherapy medication used to treat neuroblastoma. Etoposide is in the topoisomerase II inhibitor drug. It is used orally or injection into a vein. Side effects are very common: low blood cell counts, vomiting, loss of appetite, diarrhea, hair loss, and fever. Other dangerous side effects include allergic reactions and low blood pressure. For instance, Etopophos is a key product offered by Bristol-Myers Squibb.
Based on Distribution channel, the hospital pharmacies are expected to dominate the Global Neuroblastoma Drugs market during the forecast period
The hospital pharmacies held the largest share in the global neuroblastoma drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.Also the medications can only be administrated by intravenously under supervision of medical practioners at these locations.
North America region holds the largest market share global Neuroblastoma drugs market
North America holds the largest market in the global neuroblastoma drugs market due to the high incidence of cancer, according to the American cancer society, there are about 800 new cases of neuroblastoma each year in the United States. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and immunotherapy methods, the total availability of advanced technological tools, FDA approval of orphan drugs for the treatment of neuroblastoma and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Yang Li, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University conducting Phase II Study of Chemotherapy Combined with Arsenic Trioxide in Neuroblastoma.
The Global Neuroblastoma Drug Market is moderately competitive with some key competitors like Cellectar Biosciences, INC, United Therapeutics Corporation, APEIRON Biologics AG, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc, MacroGenics, Bristol-Myers Squibb Company, Eli Lilly and Company, Marsala Biotech Inc, Pfizer Inc. The growth of these companies is attributed to product launch, acquisition of independent companies and investments in multiple sectors. For instance, New Approaches to Neuroblastoma Therapy Consortium in Collaboration with United Therapeutics conducting a Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma with Dinutuximab +/- Lenalidomide.
Cellectar Biosciences, Inc
Company Overview: Cellectar Biosciences, Inc., a late-stage clinical biopharmaceutical company, is focused on the discovery, development and commercialization of drugs to treat cancer. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety due to fewer off-target effects. The company's PDC platform possesses the potential to discover and develop the next generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. They collaborated with Avicenna oncology, Orano Med to focus on the development of new PDCs.
Product Portfolio: The Company's portfolio comprised of proprietary product pipeline is comprised of multiple PDCs developed to treat a broad range of cancers. These next-generation cancer treatments aim to deliver greater efficacy and less side effects improving patient outcomes.
The company's product pipeline includes one preclinical PDC chemotherapeutic program (CLR 1900) and multiple partnered PDC assets.
OnJanuary 27, 2021 Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom's Macroglobulinemia.
On-going Phase 1 study on CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and recurrent or refractory malignant brain tumors, neuroblastoma for which there are no standard treatment options with curative potential.
The global Neuroblastoma drugs report would provide an access to an approx. 53 market data table, 46 figures and 240 pages.
LIST NOT EXHAUSTIVE